Alliance for Regenerative Medicine Releases Annual Industry Report Showcasing Impressive Sector Growth

– May 1, 2014

– Report Highlights Clinical Landscape and Financial Performance From 2013-2014 –

WASHINGTON, DC, April 28, 2014 – The Alliance for Regenerative Medicine (ARM) today announced the release of its 3rd Regenerative Medicine Annual Industry Report, an in-depth review of the continued growth and advancements in the regenerative medicine (RM) sector during the past year. The report provides a detailed overview of available RM and advanced therapy products, clinical trial breakdown by therapeutic category, anticipated 2014 milestones and financial performance across the sector. Key findings from ARM’s Pharmaceutical and Large-Cap Biotech Survey, another recent report exploring strategic viewpoints and perspectives on RM from interviews conducted with executives at 16 top companies, are also highlighted.

The Regenerative Medicine Annual Industry Report is available online at and in a limited print edition. The report’s release coincides with ARM’s 5th Annual Dinner and Legislative Fly-In (April 28-29 in Washington DC). This event is a yearly gathering of ARM’s key stakeholders including patient advocates, disease-foundation executives, and corporate and government representatives. The Annual Dinner celebrates major accomplishments in RM over the past year, while the Legislative Fly-In serves as the organization’s largest in-person advocacy effort.

The combined RM field, including cell, gene and gene modified cell therapies, generated $4.7 billion through deals, acquisitions and public and private investments from March 2013 to March 2014.  This reflects the sector’s strong potential for the treatment of chronic and life threatening diseases—today, there is a growing number of marketed products backed by a mature clinical pipeline including more than 247 companies developing 460 products and sponsoring more than 700 trials. 

“Cell- and gene-based regenerative medicine is a hotbed of progress poised to revolutionize patient care across multiple therapeutic areas including oncology, cardiovascular and ocular diseases, wound healing, autoimmune disorders and spinal cord injuries,” said Geoff MacKay, Chairman of ARM and President and CEO of Organogenesis Inc. “We are encouraged by the growth of the field in just the past 12 months as highlighted in this Industry Report, and also by the ever increasing support for regenerative medicine as evidenced by ARM’s recent Pharma Survey and the newly introduced Regenerative Medicine Promotion Act in Congress. ARM reaffirms our commitment to work with regulatory agencies, policy makers and payers to deliver cost-effective, high-value therapies that improve and save lives.”

Highlights from the report include:

An overview of the RM and advanced therapy landscape, including a clinical development breakdown by therapeutic area for 45 primary cell-based therapeutic companies, 91 stem cell and progenitor cell-based therapeutic companies, 42 cell-based immunotherapy companies and 69 gene therapy companies – 67% of the products these companies are developing are in mid to late-stage clinical trials

Milestones anticipated for 2014 including investigational new drug filings (INDs) and more than 20 clinical data readouts for heart disease, stroke, ALS, ulcerative colitis, kidney failure, various cancers and macular degeneration to name a few

A twelve-month financial overview of investment activity and market performance for the field including top deals, financings and acquisitions – financings for the year totaled $2.3 billion, significantly up from prior years

Results from the ARM Pharmaceutical and Large-Cap Biotech Survey highlighting industry perspectives on RM investing, specific areas of interest, business strategies for pursuing RM, near- and long-term therapeutic opportunities and potential challenges – 100% of the 16 companies interviewed are already investing in RM in some capacity 

“The Regenerative Medicine Annual Industry Report is an invaluable resource providing a clear snapshot of the regenerative medicine industry today and the groundbreaking advancements on the horizon,” said Morrie Ruffin, Managing Director of ARM. “We are increasingly excited about the future of regenerative medicine and the continued collaboration of all constituents as the field makes exciting progress in bringing new therapies to those who need them.”

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 150 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit